Objectives: Endothelial dysfunction plays a pivotal role in the pathophysiology of acute coronary syndromes (ACS), contributing to vascular instability and impaired perfusion. The endothelial activation and stress index (EASIX), originally developed for hematologic conditions as a marker of endothelial stress, has recently attracted interest in cardiovascular prognostication. However, its utility in ACS remains insufficiently defined. This study aimed to evaluate the prognostic performance of the original EASIX and its simplified (s-EASIX) and modified (m-EASIX) variants in predicting 30-day in-hospital mortality in ACS patients. Methods: We retrospectively analyzed 368 patients with ACS admitted to a coronary intensive care unit between June 2022 and June 2024. EASIX-based scores were calculated from admission laboratory parameters. The primary endpoint was all-cause in-hospital mortality, defined as death occurring during hospitalization or within 30 days of admission. Predictive accuracy was assessed using receiver operating characteristic (ROC) curve analysis, multivariate Cox regression, and model fit via Akaike information criterion (AIC). Results: In-hospital mortality occurred in 19 patients (5.2 %). All three scores were significantly higher among non-survivors (p<0.01). m-EASIX demonstrated the highest AUC (0.818) and sensitivity (88.2 %), followed by EASIX (AUC: 0.789) and s-EASIX (AUC: 0.709). In multivariate Cox analysis adjusted for conventional clinical variables, all scores independently predicted mortality, with s-EASIX yielding the highest hazard ratio (HR=2.149; p<0.01). EASIX achieved the best model fit (AIC=123.123). Conclusions: EASIX and its variants are independent predictors of short-term mortality in ACS. Among them, the original EASIX exhibited the most consistent overall performance, supporting its potential role in early risk stratification of critically ill cardiac patients.
9 April 2025 in Interventional Cardiology Perspectives
Effects of Sodium-glucose Co-transporter-2 Inhibitors on Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction - Interventional Cardiology Perspectives
Background/Objectives: Cytochrome P450 enzymes (CYP2D6, CYP2C19, CYP3A4) play a key role in interindividual variability in cardiovascular drug metabolism. This study aimed to describe metabolizer phenotype distributions in a Turkish emergency cardiac cohort and across diagnostic categories. Methods: This retrospective descriptive pharmacogenomic study included 250 patients. Genotyping was performed using TaqMan assays for CYP2D6 (*2, *4, *10, *41), CYP2C19 (*2, *17), and CYP3A4 (*22, *1B). Phenotypes were assigned according to CPIC guidelines. CYP2D6 copy-number variation was not assessed. Results: Non-normal metabolizer phenotypes were observed in 55.6% (CYP2D6), 84.4% (CYP2C19), and 30.4% (CYP3A4) of patients. For CYP2D6, normal (44.4%) and intermediate (42.0%) metabolizers predominated. For CYP2C19, intermediate metabolizers were most frequent (36.0%), followed by normal (22.8%), rapid (17.2%), poor (14.8%), and ultra-rapid metabolizers (9.2%). CYP3A4 showed predominantly normal activity (69.6%). Phenotype distributions varied across diagnoses without clear clustering. Conclusions: A high prevalence of CYP2D6 and CYP2C19 variability with predicted functional relevance based on CPIC was observed, whereas CYP3A4 activity was more stable. These findings provide descriptive pharmacogenomic data to support future genotype-guided cardiovascular therapy studies.